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1. Introduction 
The International Diabetes Federation estimates that near 285 million people have known 
type 2 diabetes: their number will probably double within 20 years (Shaw et al., 2010). 
Furthermore, worldwide, the number of persons with prediabetes, defined as impaired 
fasting glucose (IFG) or impaired glucose tolerance (IGT) (Genut et al., 2003), is estimated 
to be 314 million and is expected to be 418 million in 2025 (Garber et al., 2008). This 
scenario, amplified by the fact that several  subjects do not know they have diabetes 
(Garber et al., 2008), has a predictable consequence: as the prevalence and progression to 
type 2 diabetes continues to increase and the afflicted population’s age rises, the 
associated complications of diabetes inevitably will emerge as a major public health care 
issue. In 2007, for example, the direct and indirect costs related to diabetes, diabetes 
complications and general medical care amounted to $ 174 billions in the United States 
(American Diabetes Association [ADA], 2008). Thus, the advantage not only to diagnose, 
but also to recognize as soon as possible subjects at high risk to develop type 2 diabetes, is 
evident. If, on one hand, the magnitude of morbidity and early mortality attributable to 
diabetes has been clearly shown (ADA, 2008), on the other hand a growing body of 
evidence indicates that earlier detection and consequent earlier treatment of 
hyperglycaemia and related metabolic abnormalities may be beneficial (DREAM Trial 
Investigators, 2006; Knowler et al., 2002). In fact, early detection and treatment of subjects 
with prediabetes has the potential of reducing or delaying the progression to diabetes 
(DREAM Trial Investigators, 2006; Gillies et al., 2007; Knowler et al., 2002) and related 
cardiovascular disease (Chiasson et al., 2003; Ratner et al., 2005). 
The risk associated with progression to diabetes and cardiovascular complications increases 
along a continuum, rather than being threshold-dependent, and occurs at much lower 
glucose levels than those required to diagnose diabetes. Consequently, relying exclusively 
on diabetic glucose level may delay treatment (Bergman, 2010), as we need to maximize our 
efforts in diabetes prevention and early disease management.  
How can we identify not only unknown diabetics but, above all, those subjects with 
glucose levels not yet in the diabetic range, who do instead mostly need preventive 
interventions? 
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Although the increase in diabetes risk already starts at fasting plasma glucose (FPG) levels 
still within the normal range (Schulze et al., 2010; Tirosh et al., 2005), it follows that the FPG 
alone conveys inadequate information.  
Recently the American Diabetes Association (ADA) proposed the measurement of 
glycosylated haemoglobin (A1c) to stratify glucose tolerance (International Expert 
Committee, 2009). Although A1c represents an easy screening test, and it is not influenced 
by fasting, drinking a glucose solution, or waiting hours for blood drawing, we believe that 
it cannot substitute for the information obtained derived from the oral glucose tolerance test 
(OGTT). In fact the contributions of FPG and post-prandial glucose to A1c levels are not 
linear: elevated FPG is mostly responsible for higher A1c levels. Instead, borderline A1c 
values, just above the upper limits of normal, strongly depend upon post-prandial glucose 
(Monnier et al., 2003). In support of these considerations, the results of well-designed 
studies (Fajans et al., 2011; Kramer et al., 2010) substantially indicate the insufficient 
sensitivity of A1c in detecting early diabetes.  
Actually the OGTT, based on FPG and 2 h plasma glucose (2hPG) after ingestion of 75 g of 
glucose (Genut et al., 2003), is currently considered the gold standard to establish whether a 
subject has normal glucose tolerance (NGT) or altered glucose homeostasis. 
In this report, we will discuss the OGTT. In our opinion, this old test, judged obsolete and 
inaccurate to the point of being considered optional according to ADA recommendations, 
should be instead reconsidered because of its irreplaceable clinical utility. Moreover, it could 
provide clear-cut metabolic information capable of recognizing subjects endowed with a 
metabolic profile prone to a progressive derangement in glucose homeostasis, suggestive of 
a high risk to develop diabetes. 
2. The history of the OGTT  
The OGTT is an old test used to diagnose alterations in glucose metabolism; its actual design 
is the result of a continuous reshaping that has lasted decades. 
The notions that fasting hyperglycemia is too late a criterion for the early diagnosis of type 2 
diabetes and that many subjects had obvious diabetes when their glucose was measured 
after a meal, led to the development, by the 1960s, of at least six different procedures for 
standardized OGTT. This debate involved the glucose load, ranging from 50 to 100 g, 
several time-points and, especially, the choice of the diagnostic cut-off of glycemic values 
(Herman, 2007; Valleron et al., 1975). 
Based upon the analysis on the bimodal plasma glucose distribution firstly observed in 
Pima Indians, in 1979 the National Diabetes Data Group (National Diabetes Data Group, 
1979) and, subsequently, in 1997 the ADA (ADA, 1997), established the correct procedure 
and interpretation of OGTT. In particular: 
1. The standard glucose load was set at 75 g p.o.  
2. Two stages of glucose intolerance, intermediate between NGT and diabetes, were 
recognized from FPG and 2hPG: IGT was defined by a 2hPG of 140-199 mg/dl in 1979 
and confirmed in 1997, and the IFG defined by a FPG of 110-125 mg/dl in 1997. 
3. In 1997, the FPG cut-off value to diagnose diabetes was lowered from 140 to 126 mg/dl. 
It was evident that the rationale for lowering the cut-off FPG levels (126 mg/dl for diabetes 
and 110 mg/dl for IFG) was to make the OGTT, just developed and standardized, 
unnecessary. The ADA was predicting that FPG alone could stratify the different alterations 
of glucose metabolism, proceeding from NGT to diabetes with an intermediate glucose 
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intolerance step constituted by IFG. The hope was that, by eliminating the OGTT, 
considered time consuming, poorly reproducible and not well accepted by patients, a larger 
number of subjects could be efficiently screened, diagnosed and treated using FPG alone. 
Unfortunately, FPG and 2hPG are not equivalent: the first measurement, becomes altered 
mainly by an impairment in the insulin-induced stimulation of hepatic glucose uptake, 
whereas postprandial glycemia (i.e.2hPG) rises  because of delayed insulin secretion in 
combination with marked insulin resistance (Rizza, 2010). Thus, IFG and IGT are dependent 
upon different metabolic pathways.  Our group did in fact supply evidence on the diversity 
of these pre-diabetic stages: we reported a relevant impairment of insulin secretion in IFG 
and an exquisite faltering in insulin sensitivity in IGT (Carnevale Schianca et al., 2003). Thus, 
it seems that prediabetes may represent a heterogeneous entity, which does not only entail 
an increased risk of diabetes, but also of cardiovascular disease (Garber et al., 2008). The 
attempt to screen glucose tolerance using FPG alone has been disavowed by several 
epidemiological observations. At variance with one single study involving three ethnic 
groups in the United Kingdom (Unwin et al., 1998), reporting a better prediction for 
diabetes from FPG with respect to 2hPG,  FPG alone was shown to underestimate the 
diabetes prevalence when compared to 2hPG (Cheng et al., 2006; Harris et al., 1997). To 
ameliorate the diagnostic power of FPG, in 2003 the ADA lowered from 110 to 100 mg/dl its 
cut-off to define prediabetes (Genut et al., 2003). This did not meet the predicted 
expectations. As an example, a revealing study involving young African-American subjects 
compared FPG to OGTT to diagnose glucose intolerance. FPG (110 mg/dl) detected only 
27.4% of cases, OGTT 87,1%; when the 2003 ADA criteria were applied, the FPG threshold of 
100 mg/dl did not perform any better, identifying only 28.9% of glucose intolerance cases 
(Cheng et al., 2006). Furthermore, beside the evidence that FPG cannot be equated to 2hPG 
(Carnevale Schianca et al., 2003; Rizza, 2010), it has been demonstrated that 2hPG  more 
efficiently predicts the risk of heart disease than FPG (DECODE Study Group, 1998). 
Moreover, although substituting FPG for 2PG seems attractive and convenient both on 
epidemiological and clinical grounds, it does not yield any metabolically relevant 
information. The point is that it is misleading to try to assess glucose homeostasis and, at the 
same time, to stratify cardiovascular risk, without informations derived from post-prandial 
glucose metabolism. To compare the relative importance of FPG vs 2hPG in detecting 
diabetes, we studied different FPG cut-off values in detecting glucose intolerance separately 
identified by OGTT (Sainaghi et al., 2007). Out of 202 subjects with FPG ≥ 100 mg/dl, 121 
(60%) had 2hPG < 140 mg/dl; conversely, out of 452 subjects with FPG < 100 mg/dl, 61 
(14%) had a 2hPG ≥ 140 mg/dl. Choosing arbitrarily a FPG cut-off of 90 mg/dl, 33 out 266 
subjects (12%) still had abnormal 2hPG. These data clearly demonstrate that any reduction 
of FPG threshold produces a progressive rise in sensitivity coupled to a progressive fall in 
specificity in detecting high-risk subjects for diabetes. Only the simultaneous information 
obtained from 2hPG (i.e. OGTT) allows the screening to become effective. 
The next point will be explicative of the clinical utility of OGTT. 
3. The OGTT in “action” 
Despite various attempts to lower the cut-off of FPG to avoid the necessity of executing 
OGTT, there are extensive data showing that OGTT is more sensitive than FPG alone for 
diagnosing diabetes or prediabetes (Cheng et al., 2006; Harris et al., 1997; Meigs et al., 2003). 
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To illustrate the considerable clinical information obtained from the routine execution of 
OGTT, we will show the results gathered in a cohort of asymptomatic subjects attending a  
metabolic patient facility. 
A series of consecutive 1665 patients with unknown diabetes, underwent an OGTT because 
of the presence of risk factors such as obesity, hypertension, diabetes inheritability, or 
dyslipidaemia. In agreement with the 2003 ADA criteria (Genut et al., 2003), as shown in 
Fig. 1 section A, relying on FPG alone, 1023 subjects (61.4%) were NGT (FPG <100 mg/dl) 
(group 1), while 642 were affected by glucose intolerance. Of these, 561 had IFG (group 2), 
81 diabetes (group 3). As a consequence 4.9% of  subjects (group 3) could start the necessary 
treatments, including pharmacotherapy, while 33.7% (group 2), classified as prediabetics, 
should be trained to follow appropriate lifestyle changes. Obviously, the remaining 61.4% 
(group 1), considered “normal”, should perhaps be invited to follow scheduled FPG 
controls. 
 
 
Fig. 1. The stratifications of FPG and OGTT in a cohort of 1665 subjects.  
In section A it is shown the ADA 2003 FPG stratification; in section B the OGTT stratification 
in Group 1 and, in section C, in Group 2. In section D the contributions of both FPG and 
OGTT to detect subjects with diabetes are shown.  
Probably this would be the scenario if FPG were the only test executed for diabetes 
screening. Using, in addition, criteria for the metabolic syndrome or A1c would not 
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substantially increase the detection power of such a procedure (Expert Panel on detection, 
evaluation, and treatment of high blood cholesterol in adults, 2001 Fajans et al., 2011; Garber 
et al., 2008; Kramer et al., 2010). 
Will the OGTT add importantly to the previous screening? If we consider group 1 (i.e. 
subjects with FPG < 100 mg/dl), we note, as shown in Fig. 1 section B, that OGTT gives 
surprising results. A considerable proportion of these subjects (14.2%) shows abnormal 
glucose tolerance, such that 124 subjects were affected by IGT and 21 by diabetes! From 
these data, we can formulate at least two considerations. Firstly, FPG, despite the decision to 
lower its threshold to more efficiently screen glucose abnormalities (Genut et al., 2003), 
continues to exhibit low specificity; secondly, OGTT is the only way to formally diagnose 
IGT, which constitutes the basic pathophysiologic alteration of type 2 diabetes. The 
identification of IGT is a crucial step in preventive cardiovascular strategies. The 
progression to diabetes is 6% to 10% per year for patients with IGT (Garber et al., 2008) and, 
similarly, a higher cardiovascular risk with elevated 2hPG has been reported even in the 
presence of normal FPG (DECODE Study Group, 1998). Thus, using FPG alone would 
deceitfully reassure a large proportion of individuals as being NGT and who will not be 
warned on the benefits of preventive treatments.  
Let us now consider group 2, as shown in Fig. 1 (i.e. subjects with FPG 100-125 mg/dl). This 
large proportion of subjects should be labelled as affected by prediabetes and potentially 
susceptible of preventive therapies. In 2003, the ADA lowered FPG from 110 to 100 mg/dl to 
optimize sensitivity and specificity in detecting future diabetes (Genut et al., 2003). 
Nevertheless, this decision did not yield the expected results, as the development of diabetes 
in IFG varied widely (Davidson et al., 2003; Garber et al., 2008): for example, in our cohort of 
1665 subjects, the percentage of IFG subjects ranged from 13.9% to 33.7%, depending on 
whether we considered a FPG cut-off value of 110 (ADA, 1997), or of 100 mg/dl (Genut et 
al., 2003). The weakness of relying on FPG as the only mean to stratify glucose metabolism is 
then readily apparent. Moreover, the 561 IFG subjects (group 2) are far from being 
homogeneous as demonstrated by OGTT data of Fig. 1 section C: the majority of these 
subjects (n=331, 59%) has normal 2hPG, such that they should be classified as “isolated” 
IFG, whereas 29.8% (n = 167) have 2hPG 140-199 mg/dl, which indicates that are affected by  
combined IFG and IGT (IFG/IGT). Only 63 (11.2%) had real type 2 diabetes. 
It does not seem tenable to abandon OGTT in view of these data, which stress the usefulness 
of this test to correctly pinpoint, among subjects with similar IFG, those in need of a more 
accurate screening: they will be warned them about their risk of progression to diabetes, as 
well as their cardiovascular risk. Re-examining our OGTT data, these 63 subjects correctly 
identified as affected by diabetes would be promptly treated (DREAM Trail Investigators, 
2006; Knowler et al., 2002), the 167 with IFG/IGT would be considered at high 
cardiovascular risk and, also, more liable to future diabetes (Garber et al., 2008): appropriate 
preventive strategies would be undertaken. Finally, the 331 subjects correctly identified as 
affected by “isolated” IFG by virtue of their 2hPG < 140 mg/dl, are probably at lower risk 
than those whose 2hPG was ≥ 140 mg/dl (Garber et al., 2008), suggesting only lifestyle 
changes and strict follow-up as initial preventive options. The crucial conclusion is that only 
OGTT permits this differentiation.  
Fig. 1 section D shows the differential contributions of FPG versus OGTT in detecting 
subjects affected by diabetes: FPG individuated 49.1% of 165 subjects affected by diabetes, 
while OGTT allowed pinpointing an additional 50.9%. In fact, 11.2% of 561 subjects with 
www.intechopen.com
  
Medical Complications of Type 2 Diabetes 
 
32
FPG 100-125 and the 2.1% of the 1023 subjects with FPG < 100 mg/dl were truly affected by 
diabetes. This striking result emphasises the diagnostic weight of OGTT.  
As a whole, the evidence of these data demonstrates that, without OGTT, the correct clinical 
management of a devastating metabolic disease becomes inefficient. 
4. The “expansion” of OGTT 
The worldwide pandemic of diabetes entails the early detection of high risk subjects to 
provide with appropriate treatment. Unfortunately, the diabetic risk starts already when 
FPG values are still within the normal range (Tirosh et al., 2005). It seems, however, 
unreasonable to classify the vast majority of the population as at risk, as these subjects are 
presently thought to progress along a continuum similar to that of other chronic diseases, 
like hypercholesterolemia and hypertension. Thus, using the “raw” OGTT alone, although 
of crucial clinical importance, may not be sufficient. Epidemiological observations reported 
that ~ 40% of subjects who will develop diabetes exhibit NGT at baseline blood glucose 
testing, indicating that there is a large number of NGT subjects who constitute the largest 
reservoir of diabetes (Unwin et al., 2002). Moreover, the actual definition of prediabetes 
cannot provide an adequate solution of this dilemma, as not all subjects with IFG, IGT, or 
both, progress to diabetes; only 30 to 40% of IGT subjects do, in fact, ultimately convert to 
diabetes (Gerstein et al., 2007; Meigs et al., 2003). Thus, two questions arise: how to 
recognize normal subjects who will really develop diabetes in their future, and how to 
recognize prediabetic subjects who, in all likelihood, will never become diabetics. 
The present “conventional” interpretation of OGTT, as well as methods using non-OGTT 
data (Expert Panel on detection, evaluation, and treatment of high blood cholesterol in 
adults, 2001; Kolberg et al., 2009; Stern et al., 2002), do not answer this question. 
Independent from the method used, all diabetes screening programmes do not reach the 
desired sensitivity and specificity. Consequently, a large number of subjects could 
inappropriately undergo prevention or, to the contrary, be excluded from beneficial 
interventions. 
Recently, the relationship between FPG and 2hPG has been examined in a series of 
observations aimed at identifying NGT subjects at high risk for progression to diabetes 
(Abdul-Ghani et al., 2006; Abdul-Ghani et al., 2007; Abdul-Ghani et al., 2009). FPG and 
2hPG closely correlate with β-cell function (Carnevale Schianca et al., 2003), the principal 
factor responsible for the development of diabetes (Gastaldelli et al., 2004). Changes in β-
cell function also influence the shape of plasma glucose concentration profile during 
OGTT (Abdul-Ghani et al.; 2010 Tscritter et al., 2003). It has been reported that NGT 
subjects whose plasma glucose values fall faster to FPG levels during OGTT, have greater 
insulin sensitivity and better β-cell function compared to NGT subjects whose plasma 
glucose values fall more slowly (Abdul-Ghani et al., 2006; Abdul-Ghani et al., 2010; 
Carnevale Schianca et al., 2010). In agreement with the concept that the faster postload 
glucose drops towards FPG, or the lower postload glucose rises, the more efficient is β-cell 
function, we recently introduced a new dynamic appraisal of standard OGTT by 
computing the percentage increment of 2hPG with respect to FPG (PG%), by using the 
formula [(2hPG – FPG) / FPG] x 100 (Bartoli et al., 2011; Carnevale Schianca et al., 2010; 
Carnevale Schianca et al., 2011). Since FPG and 2hPG, that are not interchangeable (Unwin 
et al., 1998), as they convey different information (Carnevale Schianca et al., 2003; 
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Gastaldelli et al., 2004), PG% could reflects the fine tuning between insulin secretion and 
sensitivity. We tested PG% in relation to some estimated indexes of insulin sensitivity and 
insulin secretion derived from OGTT-data (Carnevale Schianca et al., 2010; Carnevale 
Schianca et al., 2011). Adding to glycemic measurements the simultaneous determinations 
of plasma insulin, Stumvoll et al. proposed, based  on simple statistical methods using 
stepwise linear regression analysis and conceived for different sets of OGTT’s time points, 
a series of formulas to calculate estimated indexes of insulin sensitivity and secretion 
(Stumvoll et al., 2001a). All these estimated indexes were validated by the clamp 
technique, the “gold” standard  to evaluate the β-cell function (DeFronzo et al., 1979). 
Nevertheless, the evaluation of β-cell function using gold-standard method, is not 
practically feasible for epidemiological and clinical strategies (Stumvoll et al., 2001b). 
Among all indexes proposed by Stumvoll et al. we selected those that use FPG, 2hPG and 
the corresponding plasma insulin values. So with a single test, i.e. the OGTT with 
simultaneous determination of plasma insulin, it is possible to define not only the glucose 
tolerance and the PG%, but also calculate insulin sensitivity and secretion. We reported 
that in each glucose tolerance group, the larger is PG%, the lower is insulin sensitivity 
(Carnevale Schianca et al. 2011). Since insulin sensitivity is negatively related to insulin 
secretion through a hyperbolic function (Khan, 2003), glucose metabolism is thought to 
deteriorate when the fall in insulin sensitivity is not compensated by a sufficient increase 
of  secretion. We demonstrated, for example, that NGT subjects with 2hPG near to or 
below FPG value (i.e., low PG%), are more sensitive to insulin; they do not need, then, the 
enhanced insulin secretion that, on the contrary, is necessary for NGT subjects with high 
PG%, a condition where there is a fall in insulin sensitivity (Carnevale Schianca et al., 
2010). This is, in all likelihood, attended by an elevation of 2hPG, although still remaining 
within the “normal” range: probably the 2hPG will remain “normal” until a compensatory 
insulin secretion is maintained. When this compensation fails, a derangement of glucose 
tolerance, probably heralded by a rise in PG%, is unavoidable. The PG% could therefore 
identify, within the NGT range, a distinct phenotype that may predispose to a worsening 
of glucose tolerance. As previously described in the San Antonio Metabolism study, 
subjects with 2hPG ranging from 121 to 139 mg/dl had a 60% reduction in β-cell function 
when compared to subjects with 2hPG < 120 mg/dl (Gastaldelli et al., 2004); this, and our 
data, demonstrate that β-cell function begins to deteriorate long before we can 
conventionally identify prediabetes. 
The PG% seems also useful when applied to subjects with glycaemic values within the IFG 
range. In 1997 the ADA proposed to diagnose IFG by FPG ranging from 110 to 125 mg/dl 
(American Diabetes Association, 1997) and, in 2003, widened this range by lowering the 
inferior limit of FPG to 100 mg/dl, in the attempt to better predict the development of 
diabetes (Genut et al., 2003). However, this change increased the overall prevalence of IFG 
approximately three to fourfold, without any reliable advantage in diabetes prevention 
(Davidson et al., 2003; Garber et al., 2008; Unwin et al., 2002). 
Fig.1 section A shows that the use of FPG alone allows to diagnose IFG in 561 out of 1665 
subjects (33.7%). Section C shows the improved stratification of IFG subjects obtained by 
OGTT: 59% (n=331) of these, with 2hPG < 140 mg/dl, were really affected by “isolated” IFG. 
This is an example of the utility of standard OGTT to correctly differentiate subjects with 
similar FPG. Will all these 331 subjects with isolated IFG exhibit the same risk to progress to 
diabetes? Unfortunately, the standard OGTT, although useful in correctly stratify all subjects 
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with FPG between 100 and 125 mg/dl, does not help us any further. Instead, the calculation of 
PG% could offer a possibility to recognize, even in the “isolated” IFG range, subjects with 
abnormalities in β-cell function predisposing to worsening glucose homeostasis.  
As an example, we will consider the case of a subject whose OGTT yielded FPG = 107 and 
2hPG = 110 mg/dl, and then compare him with another subject whose OGTT gave FPG = 
104 and 2hPG = 136 mg/dl. Both subjects suffer, by definition, from isolated IFG. Are they 
truly similar? 
Recently, we demonstrated that the simple calculation of PG% can differentiate subjects 
with isolated IFG into two different phenotypes, as the higher the PG% the more 
dysfunctional is the β-cell (Carnevale Schianca et al., 2011). Likewise, even in the NGT and 
IFG/IGT ranges, we noted a progressive and meaningful worsening of insulin sensitivity 
proceeding from lower to higher PG% values, while there were no changes in insulin 
secretion. Only within the NGT range was insulin secretion significantly higher in the upper 
PG% values. We speculated that this increment, probably secondary to the derangement in 
insulin sensitivity, is the prerequisite to maintain a subject within the NGT range (Carnevale 
Schianca et al., 2010). 
With this simple calculation of PG%, we add to our diagnostic tools the possibility to detect 
the pathophysiologic difference between the two IFG subjects of the above example: the first 
patient has PG% = 2.8%, the second one = 30.8%. Probably, this latter subject has an 
important deterioration of β-cell function, very likely attended, in the future, by metabolic 
consequences which could be amenable to preventive treatments. The actual definition of 
the IFG range forces us to define as prediabetes a large section of the population; the 
application of PG% can better define the real metabolic risk. As an example, considering the 
331 subjects with “isolated” IFG shown in Fig. 1 section C, 156 (47.1%) had a PG% ≤ 0%: 
their 2hPG values suggest a metabolic efficiency hardly suggestive of a risk of future 
diabetes. 
Unlike IFG, the recognition of IGT is exclusively based on OGTT, which can yield additional 
critical information if implemented by the computation of PG%. We reported that, within 
the IGT range, a major increment of PG% indicates subjects probably more liable to develop 
diabetes (Carnevale Schianca et al., 2010). Although no significant differences in insulin 
sensitivity and secretion could be disclosed considering a large spectrum of PG%, when the 
insulin secretion was corrected by insulin sensitivity to estimate β-cell function 
(Utzschneider et al., 2009), it was significantly impaired in IGT subjects with higher  PG%. 
Since not all IGT subjects progress to diabetes (Gerstein et al., 2007; Meigs et al., 2003), and 
the decline in β-cell function favours this evolution (Festa et al., 2006), PG% can identify, 
when elevated, a high-risk subgroup to which a more aggressive preventive treatment could 
be applied. 
5. Conclusions 
In conclusion, the PG% can expand the clinical weight of OGTT by simply implementing a 
more powerful and informative calculation that discloses the efficiency of β-cell function. 
When high, probably the PG% pinpoints a higher risk of worsening glucose homeostasis. 
Although prospective studies designed to test the utility of PG% are needed, this 
computation has the advantage of being simple, feasible and of being obtained by the 
standard OGTT. This old test, conceived to investigate glucose tolerance and perhaps 
hurriedly considered obsolete and unsuitable, seems, on the contrary, irreplaceable. 
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